SCHEMBL7961207

SCHEMBL7961207

Clc1ccccc1C1=CCN(CCCc2nnc3n2CCCCC3)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
CHRM2 P08172 1/20 0.43
HTR1A P08908 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA1D P25100 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
SLC6A4 P31645 1/20 0.43
ADRA1A P35348 1/20 0.43
DRD3 P35462 1/20 0.43
HTR2B P41595 1/20 0.43
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PARP1 P09874 4/20 0.40
SIGMAR1 Q99720 2/20 0.40
LMNA P02545 3/20 0.39
TSHR P16473 1/20 0.39
SHMT2 P34897 1/20 0.39
PPARG P37231 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7959202 0.92 GAA (0.41) POLBCHRM2HTR1AADRA2AADRA2B
SCHEMBL7957559 0.86 PARP1 (0.42) POLBCHRM2HTR1AADRA2AADRA2B
SCHEMBL7949039 0.85 SIGMAR1 (0.53) HTR1AGAASMN1; SMN2PARP1SIGMAR1
SCHEMBL7963975 0.84 L3MBTL1 (0.39) POLBCHRM2HTR1AADRA2AADRA2B
SCHEMBL7960974 0.83 LMNA (0.45) POLBCHRM2HTR1AADRA2AADRA2B
SCHEMBL7958937 0.83 PKM (0.52) POLBCHRM2HTR1AADRA2AADRA2B
SCHEMBL7949533 0.82 GAA (0.50) POLBGAASMN1; SMN2PARP1SIGMAR1
SCHEMBL7964099 0.81 HPGD (0.53) POLBCHRM2HTR1AADRA2AADRA2B
SCHEMBL7961350 0.81 KDM4E (0.40) POLBCHRM2HTR1AADRA2AADRA2B
SCHEMBL7949425 0.81 LMNA (0.52) POLBGAASMN1; SMN2PARP1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6187774-B1 N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2001-02-13 US disclosed
EP-0885883-A1 FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-12-23 EP disclosed